|
MVA and DNA Based SARS-CoV-2 Vaccines
Application
Modified Vaccinia virus Ankara (MVA)- and deoxyribonucleic acid (DNA)-based vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Key Benefits
Safety profile is known.
Demonstrated antiviral activity against related Coronaviruses.
Single dose of vaccination was shown to be effective against related Coronaviruses...
Published: 2/13/2025
Contributor(s): Rama Rao Amara, Sailaja Gangadhara
|
|
Vaccines and Antibody Therapeutics for HPV-related Cancers
Application
Treatment and prevention of HPV-induced malignancies.
Key Benefits
Identification of a protein expressed in a large number of HPV-induced cancers.
Antibodies have been generated that bind to the protein and potentially elicit an immune response to the cancer cells.
The antibodies can be used to develop new treatments and vaccines...
Published: 2/13/2025
Contributor(s): Rafi Ahmed, Andreas Wieland
|
|
Live Attenuated Zika Virus Vaccines
Application
Yellow fever virus-based live attenuated Zika virus (ZIKV) vaccines.
Key Benefits
Reduces neurotropism from Zika virus.
High safety and immunogenicity of chimeric vaccines.
Market Summary
Zika virus (ZIKV) belongs to the flavivirus family of viruses, which include West Nile (WN), Japanese encephalitis (JE), yellow fever (YF), dengue...
Published: 2/13/2025
Contributor(s): Baek Kim
|
|
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application
Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries.
Key Benefits
Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries.
Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 2/13/2025
Contributor(s): Ahsan Husain, Nawazish Naqvi
|
|
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application
Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax.
Key Benefits
Co-therapy increases MM sensitivity to venetoclax treatment.
Identifies patients who will respond to venetoclax therapy.
Market Summary
Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 2/13/2025
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
|
IFN Gamma Prelicensing for Improved Mesenchymal Stromal Cell Function Post-Thaw
Application
Mesenchymal stromal cells (MSC) prelicensed with pro-inflammatory cytokines for improved survival and immunosuppressive properties following cryopreservation.
Key Benefits
Preserves the immunosuppressive function of MSCs following thawing.
Improves effectiveness of transplanted MSCs following cryopreservation.
Market Summary
Mesenchymal...
Published: 2/13/2025
Contributor(s): Jacques Galipeau, Raghavan Chinnadurai
|
|
SpineGuide: Magnetic Resonance Imaging-Compatible Spinal Therapeutics Delivery System
ApplicationMRI-compatible device that enables precise delivery of therapeutic or cells to specific locations in the spinal cord. Key BenefitsCompatible with real-time MRI imaging systems allowing for the targeting and delivery of therapies concurrent with imaging. Can precisely guide and deliver a multitude of therapies (small molecules, biologics or...
Published: 2/13/2025
Contributor(s): Nicholas Boulis, John Oshinski, Jason Lamanna, Cody Anderson
|
|
A Ligand-Protease Fusion Peptide for Enhanced Tumor Targeting and Drug Delivery
Application
A ligand-protease fusion peptide that cuts through the tumor stromal barrier and provides enhanced tumor targeting and delivery efficiency for therapeutic agents.
Key Benefits
The protease activity of the fusion peptide enables breaking of the stromal matrix and allows migration into stroma-rich tumor tissues.
Can be attached to nanoparticles...
Published: 2/13/2025
Contributor(s): Lily Yang, Xiangxue Guo
|
|
GIFT4: GM-CSF and IL-4 Fusion Protein for Treating Cancer and Infectious Diseases
Application
A recombinant fusion cytokine that activates host immune responses for the treatment of cancer or infectious diseases and the development of adjuvant vaccines.
Key Benefits
Retains the immune stimulatory properties of both its parental molecules.
Displays novel functions such as direct activation of B cells leading to anti-cancer and...
Published: 2/13/2025
Contributor(s): Jacques Galipeau, Jiusheng Deng
|
|
Therapeutic for Use as an Adjunct to Psychotherapy
Application
Use of alpha-melanocyte-stimulating hormone (MSH) receptor agonists as an adjunct to psychotherapy for the treatment of autism, post-traumatic stress disorder, anxiety disorders and other behavioral disorders.
Key Benefits
Manipulating the oxytocin system in the brain has been shown to increase trust, generosity, empathy, socially reinforced...
Published: 2/13/2025
Contributor(s): Larry Young, Meera Modi
|
